Billiontoone (NASDAQ:BLLN) Price Target Raised to $125.00

Billiontoone (NASDAQ:BLLN) had its price objective boosted by JPMorgan Chase & Co. from $120.00 to $125.00 in a research note issued to investors on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other equities analysts also recently weighed in on BLLN. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. BTIG Research reduced their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday. Wells Fargo & Company reduced their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Billiontoone in a research report on Friday, May 1st. Finally, Guggenheim reduced their price objective on Billiontoone from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.43.

Billiontoone Price Performance

NASDAQ BLLN opened at $92.96 on Thursday. The stock has a market capitalization of $4.27 billion and a P/E ratio of 442.67. The firm has a 50 day moving average price of $77.96. Billiontoone has a 1-year low of $61.96 and a 1-year high of $138.70. The company has a debt-to-equity ratio of 0.18, a quick ratio of 11.32 and a current ratio of 10.92.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The business’s revenue was up 83.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.39) EPS. On average, equities research analysts anticipate that Billiontoone will post 0.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Billiontoone

Institutional investors have recently added to or reduced their stakes in the stock. Adams Street Partners LLC purchased a new stake in Billiontoone in the fourth quarter valued at $140,063,000. Baillie Gifford & Co. purchased a new stake in Billiontoone in the fourth quarter valued at $103,786,000. Price T Rowe Associates Inc. MD purchased a new stake in Billiontoone in the fourth quarter valued at $39,717,000. JPMorgan Chase & Co. purchased a new stake in Billiontoone in the fourth quarter valued at $32,078,000. Finally, Wasatch Advisors LP purchased a new stake in Billiontoone in the first quarter valued at $29,179,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.